Your argument suggests that MSB will stick with Ryoncil only and you will be happy. This contradicts everything SI has communicated to shareholders. You will also struggle to get the label extensions and “franchise” SI is promising. It is a problem now. MSB also has a pair of potential blockbuster drugs near the final hurdle, and the development of ‘3D’ has been anaemic.
IPSCs are the future of MSCs. Cynata is the furtherest developed.
CYP Price at posting:
24.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)